Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 2/3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 2Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Conditions

Breast Neoplasms 13138Neoplasms 10481Carcinoma, Non-Small-Cell Lung 6874Prostatic Neoplasms 6268Colorectal Neoplasms 5948Lung Neoplasms 5105Multiple Myeloma 3577Pancreatic Neoplasms 3563Leukemia, Myeloid, Acute 3510Neoplasm Metastasis 3508Carcinoma, Hepatocellular 3273Ovarian Neoplasms 3168Melanoma 3141Stomach Neoplasms 3057Lymphoma 2983Head and Neck Neoplasms 2604Recurrence 2557Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Leukemia 2362Colonic Neoplasms 2328Brain Neoplasms 2313Lymphoma, Non-Hodgkin 2269Rectal Neoplasms 2192Uterine Cervical Neoplasms 2191Glioblastoma 2016Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1913Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1848Esophageal Neoplasms 1801

Interventions

ivosidenib 1Magnesium 114-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
AML × Clear all
NCT06717958 2025-07-02

PIVOT

Technische Universität Dresden

Phase 2 Recruiting
76 enrolled

AML

NCT06731699 2024-12-17

A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS

Chengdu FenDi Pharmaceutical Co., Ltd.

Phase 1 Recruiting
72 enrolled

AML

NCT03275636 2024-08-07

HAMLET

DKMS gemeinnützige GmbH

Phase 2/3 Completed
98 enrolled

AML

NCT05252572 2022-02-23

Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies

Zhejiang University

Phase EARLY_PHASE1 Unknown
36 enrolled

AML

NCT05239689 2022-02-15

Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies

Zhejiang University

Phase EARLY_PHASE1 Unknown
36 enrolled

AML

NCT02418000 2019-03-20

A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations

Spirita Oncology, LLC

Phase 1/2 Terminated
27 enrolled 32 charts

AML

Data powered by HemOnc (CC BY 4.0) Colophon âš¡